Trial intelligence / Profile preview

Azacitidine versus supportive care in lower-risk transfusion-dependent myelodysplastic syndrome without del(5q)

2010-018270-20Phase 4Completed

Sponsor
Asociación Andaluza de Hematología y Hemoterapia
Start
Jun 2010
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, randomised, open-label trial of azacitidine in myelodysplastic syndrome (MDS) (2 arms), sponsored by Asociación Andaluza de Hematología y Hemoterapia. Started Jun 2010; status: completed.

02

Drugs

azacitidine
03

Conditions

myelodysplastic syndrome (MDS)

Beyond the preview

Go deeper on 2010-018270-20.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2010-018270-20.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call